Gout Flares After Stopping Anti-Inflammatory Prophylaxis: A Rapid Literature Review and Meta-Analysis.

IF 3.7 2区 医学 Q1 RHEUMATOLOGY
Lisa K Stamp, Christopher Frampton, Jeff A Newcomb, James R O'Dell, Ted R Mikuls, Nicola Dalbeth
{"title":"Gout Flares After Stopping Anti-Inflammatory Prophylaxis: A Rapid Literature Review and Meta-Analysis.","authors":"Lisa K Stamp, Christopher Frampton, Jeff A Newcomb, James R O'Dell, Ted R Mikuls, Nicola Dalbeth","doi":"10.1002/acr.25486","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this research was to determine how common gout flares are after ceasing anti-inflammatory prophylaxis.</p><p><strong>Methods: </strong>A rapid literature review and meta-analysis were undertaken. PubMed was searched from inception to February 2024. Eligibility criteria included any clinical trial of people with gout with at least one arm starting or intensifying urate-lowering therapy (ULT) with coprescription of anti-inflammatory prophylaxis and that had the percentage of participants experiencing one or more gout flares reported during and after the period of prophylaxis. Random effects meta-analyses were used to generate pooled estimates of the percentage of participants experiencing one or more flares in each period.</p><p><strong>Results: </strong>Six trials were included, together with aggregated, unpublished data from the VA STOP Gout trial (2,972 participants). Pooled random effects estimates of the percentage of participants having one or more gout flares were 14.7% (95% confidence interval [CI] 11.3-18.5%) during prophylaxis, 29.7% (95% CI 22.9-37.0%) in the three-month period after ceasing prophylaxis, and 12.2% (95% CI 6.8-19.0%) during the last study period. The mean difference in the percentage of participants having one or more gout flare while taking prophylaxis and immediately after ceasing prophylaxis was -14.8.0% (95% CI -21.2% to -8.5%; P < 0.0001). The mean difference from the period immediately following prophylaxis discontinuation compared to the last study period was 16.0% (P < 0.001). Sensitivity analyses indicated no material effects of prophylaxis duration, trial duration, ULT class, or placebo arms.</p><p><strong>Conclusion: </strong>Gout flares are common after stopping anti-inflammatory prophylaxis but return to levels seen during prophylaxis. Patients should be cautioned about the risk of gout flares and have a plan for effective gout flare management in the three months after stopping anti-inflammatory prophylaxis.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis Care & Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/acr.25486","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The aim of this research was to determine how common gout flares are after ceasing anti-inflammatory prophylaxis.

Methods: A rapid literature review and meta-analysis were undertaken. PubMed was searched from inception to February 2024. Eligibility criteria included any clinical trial of people with gout with at least one arm starting or intensifying urate-lowering therapy (ULT) with coprescription of anti-inflammatory prophylaxis and that had the percentage of participants experiencing one or more gout flares reported during and after the period of prophylaxis. Random effects meta-analyses were used to generate pooled estimates of the percentage of participants experiencing one or more flares in each period.

Results: Six trials were included, together with aggregated, unpublished data from the VA STOP Gout trial (2,972 participants). Pooled random effects estimates of the percentage of participants having one or more gout flares were 14.7% (95% confidence interval [CI] 11.3-18.5%) during prophylaxis, 29.7% (95% CI 22.9-37.0%) in the three-month period after ceasing prophylaxis, and 12.2% (95% CI 6.8-19.0%) during the last study period. The mean difference in the percentage of participants having one or more gout flare while taking prophylaxis and immediately after ceasing prophylaxis was -14.8.0% (95% CI -21.2% to -8.5%; P < 0.0001). The mean difference from the period immediately following prophylaxis discontinuation compared to the last study period was 16.0% (P < 0.001). Sensitivity analyses indicated no material effects of prophylaxis duration, trial duration, ULT class, or placebo arms.

Conclusion: Gout flares are common after stopping anti-inflammatory prophylaxis but return to levels seen during prophylaxis. Patients should be cautioned about the risk of gout flares and have a plan for effective gout flare management in the three months after stopping anti-inflammatory prophylaxis.

停止抗炎预防后痛风发作:快速文献回顾和荟萃分析。
目的:本研究的目的是确定停止抗炎预防后常见的痛风耀斑。方法:进行快速文献回顾和荟萃分析。PubMed从创立到2024年2月被搜索。入选标准包括:至少有一只手开始或强化ULT并联合处方抗炎预防的痛风患者的任何临床试验,以及在预防期间和之后报告的≥一次痛风发作的参与者的百分比。随机效应荟萃分析用于对每个时期经历≥一次耀斑的参与者的百分比进行汇总估计。研究结果:包括6项试验,以及VA-STOP痛风试验(2972名参与者)汇总的未发表数据。受试者≥一次痛风发作的合并随机效应估计(95% CI)在预防期间为14.7%(11.3%-18.5%),在停止预防后的三个月期间为29.7%(22.9%-37.0%),在最后一个研究期间为12.2%(6.8%-19.0%)。在预防期间和停止预防后立即出现≥一次痛风耀斑的参与者百分比的平均差异为-14.8.0%(-21.2%至-8.5%)(解释:停止抗炎预防后痛风耀斑很常见,但会恢复到预防期间的水平。患者应警惕痛风发作的风险,并在停止抗炎预防后的三个月内制定有效的痛风发作管理计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.40
自引率
6.40%
发文量
368
审稿时长
3-6 weeks
期刊介绍: Arthritis Care & Research, an official journal of the American College of Rheumatology and the Association of Rheumatology Health Professionals (a division of the College), is a peer-reviewed publication that publishes original research, review articles, and editorials that promote excellence in the clinical practice of rheumatology. Relevant to the care of individuals with rheumatic diseases, major topics are evidence-based practice studies, clinical problems, practice guidelines, educational, social, and public health issues, health economics, health care policy, and future trends in rheumatology practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信